ArticleScientific reports2025
In vitro study on the bacteriostatic effect of Amoxicillin-loaded Nano-hydroxyapatite and its capability in occluding dentinal tubules.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study explores the potential of Carboxymethy Cellulose/Amoxicillin/Nano-Hydroxyapatite suspensions (CMC/AMX/nHA) for the treatment of dentin hypersensitivity, particularly in the context of periodontitis treatment. The CMC/AMX/nHA suspension was compared with the commonly used clinical desensitizing agent Bifluorid12 and the broad-spectrum antibiotic Minocycline Hydrochloride. Microscopic observation and antimicrobial experiments were conducted to quantitatively and qualitatively assess the ability of CMC/AMX/nHA to seal dentinal tubules and its antimicrobial properties. Additionally, a resin bonding experiment was performed to evaluate the effect of CMC/AMX/nHA on dentin bonding. The research results indicate that CMC/AMX/nHA demonstrates good biocompatibility, with excellent drug delivery capabilities, bacterial growth inhibition, and no interference with subsequent repair treatments during desensitization therapy. These findings suggest that CMC/AMX/nHA has high translational potential and may be effectively applied in clinical oral medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.